Literature DB >> 12183271

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.

William E Delaney1, Ros Edwards, Danni Colledge, Tim Shaw, Phil Furman, George Painter, Stephen Locarnini.   

Abstract

The phenylpropenamide derivatives AT-61 and AT-130 are nonnucleoside analogue inhibitors of hepatitis B virus (HBV) replication. They inhibited the replication of wild-type HBV with 50% inhibitory concentrations of 21.2 +/- 9.5 and 2.40 +/- 0.92 micro M, respectively, compared to 0.064 +/- 0.020 micro M lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12183271      PMCID： PMC127422          DOI： 10.1128/AAC.46.9.3057-3060.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

Authors:  B Seignères; C Pichoud; S S Ahmed; O Hantz; C Trépo; F Zoulim
Journal:  J Infect Dis       Date:  2000-04-13       Impact factor: 5.226

Review 2.  Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.

Authors:  L J Stuyver; S A Locarnini; A Lok; D D Richman; W F Carman; J L Dienstag; R F Schinazi
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

3.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 4.  Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.

Authors:  E Doo; T J Liang
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

5.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.

Authors:  S K Ono; N Kato; Y Shiratori; J Kato; T Goto; R F Schinazi; F J Carrilho; M Omata
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

6.  A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B.

Authors:  R A de Man; P Marcellin; F Habal; P Desmond; T Wright; T Rose; R Jurewicz; C Young
Journal:  Hepatology       Date:  2000-08       Impact factor: 17.425

7.  Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.

Authors:  L Fu; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication.

Authors:  R B Perni; S C Conway; S K Ladner; K Zaifert; M J Otto; R W King
Journal:  Bioorg Med Chem Lett       Date:  2000-12-04       Impact factor: 2.823

Review 9.  Combination chemotherapy for hepatitis B virus: the path forward?

Authors:  T Shaw; S Locarnini
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

10.  Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.

Authors:  C Ying; E De Clercq; W Nicholson; P Furman; J Neyts
Journal:  J Viral Hepat       Date:  2000-03       Impact factor: 3.728
View more
  53 in total

Review 1.  Present and future therapies of hepatitis B: From discovery to cure.

Authors:  T Jake Liang; Timothy M Block; Brian J McMahon; Marc G Ghany; Stephan Urban; Ju-Tao Guo; Stephen Locarnini; Fabien Zoulim; Kyong-Mi Chang; Anna S Lok
Journal:  Hepatology       Date:  2015-10-27       Impact factor: 17.425

Review 2.  Antiviral therapies and prospects for a cure of chronic hepatitis B.

Authors:  Fabien Zoulim; David Durantel
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 3.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

Review 4.  Emerging drugs for hepatitis B.

Authors:  Fabien Zoulim
Journal:  Expert Opin Emerg Drugs       Date:  2007-05       Impact factor: 4.191

Review 5.  The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals.

Authors:  Ahmed Diab; Adrien Foca; Fabien Zoulim; David Durantel; Ourania Andrisani
Journal:  Antiviral Res       Date:  2017-11-26       Impact factor: 5.970

Review 6.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

7.  Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.

Authors:  Ahmed Diab; Adrien Foca; Floriane Fusil; Thomas Lahlali; Pascal Jalaguier; Fouzia Amirache; Lia N'Guyen; Nathalie Isorce; François-Loïc Cosset; Fabien Zoulim; Ourania Andrisani; David Durantel
Journal:  Hepatology       Date:  2017-11-06       Impact factor: 17.425

8.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

Review 9.  Hepatitis B virus resistance to antiviral drugs: where are we going?

Authors:  Fabien Zoulim
Journal:  Liver Int       Date:  2011-01       Impact factor: 5.828

10.  A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion.

Authors:  Anne Marie Dougherty; Haitao Guo; Gael Westby; Yuanjie Liu; Ender Simsek; Ju-Tao Guo; Anand Mehta; Pamela Norton; Baohua Gu; Timothy Block; Andrea Cuconati
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.